Open HandWomen, justice and the game

Meningioma Symptoms in Women: Signs, Diagnosis, Treatment and Hormones

Updated

Clay model of a small MRI room: a scanner with a round opening, a sliding patient table with a folded towel and a side cart.

Short answer

Meningioma symptoms depend on where the tumor presses: the National Cancer Institute lists vision changes, loss of hearing or smell, confusion, seizures and headaches that are worse in the morning.1 Many meningiomas cause no symptoms at all and turn up on a scan done for another reason.2

On this page (12)

What a meningioma is

A meningioma is a tumor that grows from the meninges, the layers of tissue that wrap the brain and spinal cord. It forms along the dura mater, the tough outer layer, so it usually sits on the surface of the brain and pushes against it from outside. It is the most common primary brain tumor, meaning one that starts in the central nervous system and has not spread there from somewhere else.1

Doctors sort meningiomas into three grades by how the cells look under a microscope. Grade 1 tumors are low grade and slow growing; grade 2, called atypical, are more likely to come back after removal and can invade nearby bone; grade 3, or anaplastic, are malignant and fast growing.1 Grade 1 accounts for 80.5 percent of all meningiomas, grade 2 for 17.7 percent and grade 3 for 1.7 percent.2

Most meningiomas therefore behave like slow, benign growths. They can still cause harm. A tumor that is not cancer in the strict sense can grow large enough to press on nerves, blood vessels or brain tissue, and the effects depend on the exact spot. The American Association of Neurological Surgeons notes that in some locations a large meningioma can be severely disabling and even life threatening.3

How common meningiomas are, and why women have more of them

In the national US registry data for 2012 to 2016, meningiomas made up 37.6 percent of all primary brain and spinal cord tumors. The average yearly rate was 8.6 per 100,000 people, the highest of any tumor of that kind, and the median age at diagnosis was 66.3 Risk rises with age: the rate in people over 40 was 18.69 per 100,000, against 0.16 per 100,000 in those under 20.2

Women carry most of that burden. In US registry figures cited by a 2021 review, benign meningiomas were 2.33 times as common in women as in men, while for malignant ones the ratio was only 1.12. Below the age of 20, girls and boys had similar rates.2 The National Cancer Institute adds that grade 1 tumors are more common in women and grades 2 and 3 more often affect men.1 Small, silent meningiomas are also common: autopsy studies usually find one in 2 to 3 percent of people.2

The gap between the sexes is one reason researchers have long looked at hormones. Most meningiomas carry receptors for sex hormones: roughly 88 percent have progesterone receptors and about 40 percent estrogen receptors, according to that review, published in the journal Biomedicines. It also found earlier studies of birth control pills, hormone replacement therapy and pregnancy history inconsistent, though two meta-analyses and several other studies linked hormone replacement therapy to higher risk.2

Meningioma symptoms by location

Because a meningioma grows slowly, the brain often adapts for years, and meningioma symptoms tend to creep in. Across the case series summarized in the Biomedicines review, the most frequent signs at diagnosis were headache (33.3 to 36.7 percent of patients), a problem with one of the cranial nerves (28.8 to 31.3 percent), seizures (16.9 to 24.6 percent), changes in thinking (14.4 percent) and weakness (11.1 percent). About 9.4 percent had no symptoms.2

Tumors at the base of the skull more often cause nerve problems, while those elsewhere are more likely to cause seizures.2 The headings below follow the main locations.

Front of the brain and behind the forehead

Meningiomas in the front of the skull, including those over the olfactory groove that carries the nerves for smell, are often large by the time they are found. Patients in these series reported impaired vision (54 percent), headache (48 percent), loss of smell (40 percent) and seizures (20 percent).2 Some show slow changes in behavior: apathy, poor judgment or what relatives describe as a different personality. Tumors along the front of the falx, the fold of dura between the two halves of the brain, can bring a long history of headache with these changes.2

Around the eyes and the optic nerves

A tumor near the tuberculum sellae, just above the pituitary gland, usually causes gradual loss of vision in one eye, later followed by blind spots in the other. A meningioma on the outer sphenoid wing, behind the eye socket, often pushes one eye forward without pain before vision in that eye fades.2

Along the top of the brain

Parasagittal meningiomas, which sit beside the midline at the top of the head, can grow large before anyone notices. When they cause symptoms, these are typically headache or seizures that start in the legs.2 Tumors over the temporal lobe often show up through seizures as well.

At the back of the head and in the spine

In the posterior fossa, the space for the cerebellum and brainstem, a meningioma can block the flow of spinal fluid. The result can be swelling of the optic nerve and headache early in the morning.2 Spinal meningiomas are most common in the chest section of the spine and cause slowly worsening stiffness and weakness in the legs, sometimes with pain at night.2

Typical signs by tumor location

Common presenting signs of meningioma, by location, as summarized in a 2021 review
LocationTypical signs
Front of the skull and olfactory grooveVision problems, headache, loss of smell, seizures, slow personality change2
Near the optic nerves (tuberculum sellae)Gradual vision loss in one eye, later blind spots in the other2
Outer sphenoid wingPainless bulging of one eye, then vision loss on that side2
Parasagittal, top of the brainHeadache, seizures beginning in the legs; may be large before symptoms2
Temporal lobeSeizures2
Posterior fossaMorning headache, optic nerve swelling from blocked spinal fluid2
SpineSlowly worsening leg stiffness and weakness, sometimes night pain2

Headaches and when a doctor should hear about them

Most headaches have nothing to do with a tumor, and none of these signs proves one. MedlinePlus, the National Library of Medicine's health site, describes the headache pattern that can point to a brain tumor: worse on waking and easing within a few hours, waking a person from sleep, or getting worse with coughing, exercise or a change of position.4

The same page advises contacting a health care provider about any new or persistent headache, and going to a provider or an emergency room for a new seizure, sudden drowsiness or stupor, or a sudden change in vision or speech.4 Only a clinician can sort out what a symptom means, and the first step is usually a neurological examination and a decision about imaging.

How a meningioma is diagnosed

Imaging makes the first diagnosis. The usual test is MRI of the head; a contrast-enhanced CT scan is used in people who cannot have MRI, such as some patients with pacemakers.2 On MRI a meningioma typically lights up strongly and evenly after an injection of gadolinium contrast. About 72 percent show a dural tail, a thin trail of enhancing dura running from the tumor's edge, which helps radiologists tell a meningioma from other tumors outside the brain.2

CT picks up calcium deposits inside the tumor and thickening of the skull bone better than MRI does. A newer PET scan uses tracers that bind to somatostatin receptor 2, which almost every meningioma carries, to separate tumor from healthy tissue.2 Because meningiomas grow in typical places, imaging is often enough to make the diagnosis.2

The grade, however, needs tissue. When surgery is done, a neuropathologist examines the removed tumor to confirm that it is a meningioma and to assign its grade.1 For a small tumor found by chance and left in place, the grade stays an inference from its appearance and its behavior on later scans.

Treatment: watchful waiting, surgery and radiation

Many meningiomas never need an operation. For a small tumor (3 centimeters across or less) found incidentally and causing no symptoms, a common approach is observation: repeat MRI scans until the tumor causes symptoms or grows large enough to treat, and some never change.2 The European Association of Neuro-Oncology suggests a contrast MRI 6 months after diagnosis, then once a year for 5 years if nothing changes, and every 2 years after that.2

Surgery is the main treatment for a meningioma that causes symptoms, grows during observation, or is large enough to cause trouble soon. Removing the whole tumor cures 70 to 80 percent of patients. How completely a surgeon can remove it depends on the location, on whether the tumor wraps around veins, nerves or arteries, and on the patient's general health; surgeons record the result on the five-step Simpson scale, which predicts the chance of regrowth.2

Radiation is used when a tumor cannot be removed safely, when some is left behind, or when it comes back. Stereotactic radiosurgery delivers one focused high dose to small tumors under 3 centimeters; larger ones get fractionated radiotherapy, the same total dose split into many smaller sessions.2 Grades 2 and 3 return often even after complete removal, at rates of 30 to 40 percent and 50 to 80 percent within 5 years, so radiation usually follows surgery for those grades.2 For high-grade meningiomas as a group, the National Cancer Institute gives a relative five-year survival rate of 63.5 percent.1

Which of these paths fits a given patient is a decision for a neurosurgeon, often together with a radiation oncologist, and it turns on size, location, symptoms, age and health. The figures above describe groups of patients, not any one person.

Progestogens and meningioma: what the studies show

Progestogens are drugs that act like the hormone progesterone. They are used in contraceptives such as the Depo-Provera shot, in menopause hormone therapy and in treatments for gynecological conditions. Much of the evidence on whether some of them promote meningiomas comes from France's national health records, which cover prescriptions for the whole population.5

The 2024 BMJ study by Roland and colleagues

In March 2024, Noémie Roland and six co-authors published a national case-control study in The BMJ using France's health data system. They compared 18,061 women who had brain surgery for meningioma between 2009 and 2018 with 90,305 matched women who had not.5 Three drugs used as reference points showed very high odds of use among the cases: cyproterone acetate (odds ratio 19.21), nomegestrol acetate (4.93) and chlormadinone acetate (3.87).5

Among the drugs under study, the injectable form of medroxyprogesterone acetate, the active ingredient of Depo-Provera, had an odds ratio of 5.55, medrogestone 3.49 and promegestone 2.39, with the excess driven by use of a year or more.5 Progesterone itself, dydrogesterone and levonorgestrel intrauterine devices showed no excess risk. The authors called the findings on the injectable and on the hormonal IUDs important new results.5 A closer look at the study's raw numbers is on the Depo-Provera risks page.

A US study and two reviews

A 2025 study in JAMA Neurology by Xiao and six co-authors used the TriNetX records of US health systems from 2004 to 2024. After matching, women who used the shot had a relative risk of 2.43 for a meningioma diagnosis compared with women on no hormonal method, and the excess was confined to those with more than four years of use or who started after age 31.6 Oral medroxyprogesterone acetate carried a small increase (1.18), and no other contraceptive showed one. The number needed to harm was 1,152, meaning roughly one extra diagnosis for every 1,152 women using the shot; the authors judged the overall clinical risk low.6

A meta-analysis in EClinicalMedicine in February 2026 pooled six studies of the shot and found an odds ratio of 2.68, which the authors rated as low-certainty evidence; the results of those studies varied widely. Cyproterone acetate, at 12.36, had the strongest link, and no signal appeared for levonorgestrel, progesterone or dydrogesterone.7 Studies in the review reported tumors shrinking after cyproterone or nomegestrol acetate was stopped.7

In April 2026, a team of neurosurgeons writing in Neurosurgery described 38 women with meningiomas after at least two years of uninterrupted shot use, a median of 129 months. Compared with unexposed patients, their tumors were more often multiple, invaded bone in 50 percent of cases against 17.5 percent, and all carried progesterone receptors.8 The authors wrote that stopping the drug and observing the tumor before surgery should be considered for lesions without symptoms, while noting that the idea still needs testing in prospective studies.8

The December 2025 FDA label change

Pfizer submitted a request to add meningioma information to the Depo-Provera labels on February 5, 2024. The FDA answered with an action letter on November 1, 2024; Pfizer amended its application on June 12, 2025, and the agency approved the change in a letter signed on December 12, 2025, for both Depo-Provera CI and depo-subQ provera 104.9 The approval added the information to the warnings section, the patient counseling section and the patient leaflet.9

Section 5.4 of the current prescribing information states that meningiomas have been reported after repeated use of medroxyprogesterone acetate, mostly with long-term use, and tells clinicians to monitor patients for signs and symptoms and to stop the drug if a meningioma is diagnosed. Clinicians are also told to counsel patients with a history of meningioma about the possible risk that it worsens.10 The patient information now lists a possible increased risk for growth of a meningioma, mainly when the product is used for a long time, and asks patients to tell their health care professional if they have ever had one.10

The label change runs alongside the federal product liability litigation over the shot; the Depo-Provera settlement page follows that case. More guides on women's health are collected under Health.

Questions about meningioma symptoms

What are the first symptoms of a meningioma?

Often there are none. When symptoms appear, headache is the most frequent, followed by problems with a cranial nerve such as vision or smell, seizures, changes in thinking and weakness. About 9.4 percent of patients in published series had no symptoms at diagnosis.2

Can a meningioma be found without symptoms?

Yes. Many are found on a scan done for another reason, and autopsy studies usually find a meningioma in 2 to 3 percent of people.2 A small tumor without symptoms is often watched with repeat MRI instead of being removed straight away.2

Is a meningioma cancer?

Most are not. About 80.5 percent are grade 1, slow-growing tumors with benign cells; 1.7 percent are grade 3, which is malignant.2 Even a benign meningioma can cause serious problems if it presses on the brain or nerves.

Does Depo-Provera cause meningioma?

Observational studies link long-term use of the shot to higher odds of meningioma, and since December 2025 the US label carries a meningioma warning.5,10 These studies show an association, and the absolute risk for an individual user is low; a US study estimated one extra diagnosis per 1,152 users.6

References

Sources 10

  1. Meningioma
    National Cancer Institute · NCI-CONNECT
    Government Aug 20, 2024 cancer.gov
    ↩
  2. Meningioma: A Review of Epidemiology, Pathology, Diagnosis, Treatment, and Future Directions
    Ogasawara C, Philbrick BD, Adamson DC · Biomedicines
    Research Mar 2021 pubmed.ncbi.nlm.nih.gov
    ↩
  3. Meningiomas
    American Association of Neurological Surgeons
    Organization Retrieved Nov 2026 aans.org
    ↩
  4. Brain tumor - primary - adults
    MedlinePlus, U.S. National Library of Medicine
    Government Oct 21, 2025 medlineplus.gov
    ↩
  5. Use of progestogens and the risk of intracranial meningioma: national case-control study
    Roland N, Neumann A, Hoisnard L, et al. · The BMJ
    Research Mar 27, 2024 pubmed.ncbi.nlm.nih.gov
    ↩
  6. Depot Medroxyprogesterone Acetate and Risk of Meningioma in the US
    Xiao T, Kumar P, Lobbous M, et al. · JAMA Neurology
    Research Nov 2025 pubmed.ncbi.nlm.nih.gov
    ↩
  7. Progestogen use and the risk of intracranial meningioma: a systematic review and meta-analysis
    Hudelist B, Roux A, Huet-Mignaton E, et al. · EClinicalMedicine
    Research Feb 2026 pubmed.ncbi.nlm.nih.gov
    ↩
  8. Pattern of Intracranial Meningiomas Associated With Prolonged DMPA Use
    Abou-Al-Shaar H, Wrigley R, Passeri T, et al. · Neurosurgery
    Research Apr 21, 2026 pubmed.ncbi.nlm.nih.gov
    ↩
  9. Supplement approval, NDA 020246/S-074 and NDA 021583/S-045
    U.S. Food and Drug Administration
    Government Dec 12, 2025 accessdata.fda.gov PDF
    ↩
  10. Depo-Provera CI (medroxyprogesterone acetate) injectable suspension, prescribing information
    Pfizer (Pharmacia & Upjohn) · DailyMed
    Government Dec 2025 dailymed.nlm.nih.gov
    ↩